Search research articles
Contact Us
Filters
Showing results (61-70 of 75) with videos related to
Page
of 8
Sort By:
Nature Communications
|
April 1, 2024
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
Yang Zhou, Partho Sarothi Ray, Jianguo Zhu, et al.
The Oncologist
|
July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
Silvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Acta Oncologica (Stockholm, Sweden)
|
March 27, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Anne Hansen Ree, Vigdis Nygaard, Kjetil Boye, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Nature Communications
|
May 29, 2021
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M Stütz, Didier Surdez, et al.
British Journal of Cancer
|
August 27, 2022
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
Tatiana Georgiesh, Ninna Aggerholm-Pedersen, Patrick Schöffski, et al.
ESMO Open
|
August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
Anne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 75) with videos related to
Sort By:
Page
of 8
Nature Communications
|
April 1, 2024
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
Yang Zhou, Partho Sarothi Ray, Jianguo Zhu, et al.
The Oncologist
|
July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
Silvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Acta Oncologica (Stockholm, Sweden)
|
March 27, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Anne Hansen Ree, Vigdis Nygaard, Kjetil Boye, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Nature Communications
|
May 29, 2021
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M Stütz, Didier Surdez, et al.
British Journal of Cancer
|
August 27, 2022
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
Tatiana Georgiesh, Ninna Aggerholm-Pedersen, Patrick Schöffski, et al.
ESMO Open
|
August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
Anne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
Page
of 8